ABP 501, a Proposed Biosimilar to Adalimumab: Functional Similarity Adds to the Totality of Evidence in Support for Biosimilarity in All Approved Indications of Use

被引：0
|
作者：
McBride, Helen
Kuhns, Scott
Born, Teresa L.
Kaur, Primal
机构：
来源：
GASTROENTEROLOGY | 2016年 / 150卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(16)31347-6
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1858
引用
收藏
页码：S383 / S383
页数：1
相关论文
共 8 条
  • [1] Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
    Jyoti Velayudhan
    Yuh-feng Chen
    Amanda Rohrbach
    Christina Pastula
    Gwen Maher
    Heather Thomas
    Ryan Brown
    Teresa L. Born
    BioDrugs, 2016, 30 : 339 - 351
  • [2] Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
    Velayudhan, Jyoti
    Chen, Yuh-feng
    Rohrbach, Amanda
    Pastula, Christina
    Maher, Gwen
    Thomas, Heather
    Brown, Ryan
    Born, Teresa L.
    BIODRUGS, 2016, 30 (04) : 339 - 351
  • [3] Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
    Liu, Jennifer
    Eris, Tamer
    Li, Cynthia
    Cao, Shawn
    Kuhns, Scott
    BIODRUGS, 2016, 30 (04) : 321 - 338
  • [4] Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
    Jennifer Liu
    Tamer Eris
    Cynthia Li
    Shawn Cao
    Scott Kuhns
    BioDrugs, 2016, 30 : 321 - 338
  • [5] A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
    Richard Markus
    Helen J. McBride
    Monica Ramchandani
    Vincent Chow
    Jennifer Liu
    Dan Mytych
    Gary Fanjiang
    Advances in Therapy, 2019, 36 : 1833 - 1850
  • [6] A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
    Markus, Richard
    McBride, Helen J.
    Ramchandani, Monica
    Chow, Vincent
    Liu, Jennifer
    Mytych, Dan
    Fanjiang, Gary
    ADVANCES IN THERAPY, 2019, 36 (08) : 1833 - 1850
  • [7] Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501.
    Born, Teresa
    Velayudhan, Jyoti
    Chen, Yuhfung
    Thomas, Heather
    Pastula, Christina
    Maher, Gwen
    Brown, Ryan
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S661 - S661
  • [8] The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product
    McClellan, Joseph E.
    Conlon, Hugh D.
    Bolt, Michael W.
    Katfayan, Vatche
    Palaparthy, Rameshraja
    Rehman, Muhammad, I
    Kirchhoff, Carol F.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
1